Anton Belousov Selected Research

glofitamab

1/2022	Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma.
1/2021	Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Anton Belousov Research Topics

Disease

8	Neoplasms (Cancer) 01/2022 - 01/2013
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2022 - 01/2021
2	Carcinoma (Carcinomatosis) 01/2018 - 01/2018
2	Emphysema 01/2015 - 10/2013
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2021
1	Parkinsonian Disorders (Parkinsonism) 01/2021
1	Synucleinopathies 01/2021
1	REM Sleep Behavior Disorder 01/2021
1	Parkinson Disease (Parkinson's Disease) 01/2021
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 11/2020
1	Hepatocellular Carcinoma (Hepatoma) 02/2018
1	Colonic Neoplasms (Colon Cancer) 01/2016
1	Pathologic Complete Response 01/2014
1	Chronic Obstructive Pulmonary Disease (COPD) 10/2013

Drug/Important Bio-Agent (IBA)

5	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2013
3	ParaffinIBA 01/2014 - 01/2013
3	Formaldehyde (Formol)FDA Link 01/2014 - 01/2013
2	glofitamabIBA 01/2022 - 01/2021
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2021
1	Peptide Hydrolases (Proteases)FDA Link 01/2021
1	SynucleinsIBA 01/2021
1	alpha-SynucleinIBA 01/2021
1	Blocking AntibodiesIBA 11/2020
1	atezolizumabIBA 11/2020
1	GlypicansIBA 02/2018
1	codrituzumabIBA 02/2018
1	Monoclonal AntibodiesIBA 02/2018
1	Proteins (Proteins, Gene)FDA Link 02/2018
1	human ERBB2 proteinIBA 01/2018
1	Phenobarbital (Luminal)FDA Link 01/2018
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2018
1	Estrogen Receptor alphaIBA 01/2018
1	ErbB Receptors (EGF Receptor)IBA 01/2018
1	Bispecific AntibodiesIBA 02/2016
1	CytokinesIBA 02/2016
1	Folate Receptor 1IBA 02/2016
1	Bevacizumab (Avastin)FDA Link 01/2016
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2016
1	vanucizumabIBA 01/2016
1	Omalizumab (Xolair)FDA Link 01/2016
1	Immunoglobulin E (IgE)IBA 01/2016
1	RetinoidsIBA 01/2015
1	Fluorouracil (Carac)FDA LinkGeneric 01/2014
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2014
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2014
1	RNA (Ribonucleic Acid)IBA 01/2014
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2014
1	Trastuzumab (Herceptin)FDA Link 01/2014
1	Methotrexate (Mexate)FDA LinkGeneric 01/2014
1	Receptor for Advanced Glycation End ProductsIBA 10/2013
1	Genetic Markers (Genetic Marker)IBA 05/2013

Therapy/Procedure

1	Immunotherapy 11/2020
1	Mastectomy (Mammectomy) 01/2018
1	Aftercare (After-Treatment) 01/2016
1	Drug Therapy (Chemotherapy) 01/2014